Paget disease | AIPGMEE Preparations

The bisphosphonate currently approved for intravenous use in 'Paget disease'.
A. Etidronate 
B. Pamidronate
C. Alendronate 
D. Risedronate

Ans. B. Pamidronate

BISPHOSPHONATES

The bisphosphonates are analogues of pyrophosphate, with high affinity for bone, especially in areas of increased bone turn over, where they are powerful inhibitors of bone resorption. The bisphosphonates are concentrated in areas of high bone turn over and are taken up by and inhibit osteoclast action. The potency of the compounds for inhibition of bone resorption varies a thousand fold, increasing in the order of etidronate, tiludronate, pamidronate, alendronate, and risdronate. Pamidronate is the only bisphosphanate currently approved for intravenous use in paget disease